|Day Low/High||3.14 / 3.22|
|52 Wk Low/High||2.58 / 5.66|
Investors in Achillion Pharmaceuticals Inc saw new options become available this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACHN options chain for the new February 2018 contracts and identified the following call contract of particular interest.
The most recent short interest data has been released for the 11/30/2017 settlement date, which shows a 1,585,169 share decrease in total short interest for Achillion Pharmaceuticals Inc. , to 7,056,852, a decrease of 18.34% since 11/15/2017.
Investors in Achillion Pharmaceuticals Inc. saw new options become available this week, for the June 2018 expiration.
Robust balance sheet to support global expansion of ACH-4471 clinical development program in PNH and C3G
- 98.9% SVR12 achieved following six weeks of therapy for patients with chronic HCV genotypes 1, 2, 4, 5, or 6 -
Healthcare giant Johnson & Johnson cut costs by laying off 297 staffers tied to its insulin pump business, while also buying a German surgical software company and inking a deal with biotech company targeting hepatitis B treatments.
Wall Street starts the week with a rally.
The Dow is up more than 250 points.
The New Haven, Conn.-based firm on Sept. 9 received a termination notice regarding its license and collaboration pact with Johnson & Johnson's Janssen Pharmaceuticals Inc. on hepatitis C.
Thursday's downgrade is in part based on a lack of confidence in Achillion's CH-4471 to compete with Alexion Pharmaceuticals' Soliris treatment.
- Conference call and live webcast will begin at 4:05 p.m. ET on August 8, 2017 -
Investors in Achillion Pharmaceuticals Inc. saw new options begin trading today, for the March 2018 expiration.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.